John Zajecka to Administration, Intranasal
This is a "connection" page, showing publications John Zajecka has written about Administration, Intranasal.
Connection Strength
0.269
-
Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series. J Clin Psychiatry. 2023 02 01; 84(2).
Score: 0.225
-
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019 09 01; 76(9):893-903.
Score: 0.044